Mandatory notification of trade in connection with grant of options to CEO
EXACT Therapeutics AS – Mandatory notification of trade in connection with grant of options to CEO
OSLO/LONDON, 30 September 2022: EXACT Therapeutics AS ("EXACT-Tx" or the "Company") has today granted 610,643 share options to the Company's CEO and primary insider, Per Walday. Each option, when exercised, gives the right to acquire one share in the Company. The shares will be subject to a 12-month lock-up, subject to certain exemptions.
The share options have a ten (10) year term and vest over a period of 36 months, whereby 25% vest after 12 months, 25% vest after 24 months and 50% vest after 36 months. All options have an exercise price of NOK 15, which is subject to adjustment in the event of i) a change in the share capital, ii) a rights issue or repair issue, or iii) dividends or other distributions in cash or in kind.
Following the grant, Per Walday holds a total of 610,643 share options and 0 shares in the Company.
This information is subject to the disclosure requirements in Regulation EU 596/2014 (MAR) article 19 number 3 and section 5-12 of the Norwegian Securities Trading Act.
A primary insider notification pursuant to the EU Market Abuse Regulation Article 19 is attached hereto.
For more information, please contact:
Per Walday, CEO, per.walday@exact-tx.com
About EXACT-Tx:
EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drug targeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com